Helius Medical Technologies
Helius Medical Technologies is a leading neurotech company focused on neurologic deficits, utilizing non-invasive platform technologies to enhance neuroplasticity and improve the lives of individuals with neurological diseases. Their mission is to develop and expand treatment options that increase independence and quality of life for patients with neurological conditions, with a vision to become the standard of care in neuromodulation therapy.
Industries
Nr. of Employees
small (1-50)
Helius Medical Technologies
642 Newtown Yardley Rd., Ste 100, Newtown, PA 18940
Products
Portable translingual neuromodulation system
A prescription-only, non-implantable system comprising a controller and intra-oral mouthpiece that delivers mild electrical stimulation to the tongue to elicit neuromodulatory signals to brainstem and cortical regions; intended for use as an adjunct to supervised therapeutic exercise to improve gait and balance over a short-term protocol.
Portable translingual neuromodulation system
A prescription-only, non-implantable system comprising a controller and intra-oral mouthpiece that delivers mild electrical stimulation to the tongue to elicit neuromodulatory signals to brainstem and cortical regions; intended for use as an adjunct to supervised therapeutic exercise to improve gait and balance over a short-term protocol.
Services
Web-based training program to educate and certify rehabilitation specialists in supervised delivery of neuromodulation-plus-physical-therapy protocols.
Company-sponsored multicenter observational and interventional studies to evaluate adherence, functional outcomes, and long-term effects of neuromodulation-plus-therapy programs in MS, stroke, and TBI.
Field-based medical science liaison activities to engage investigators, support publications, respond to medical inquiries, and develop KOL networks.
Web-based training program to educate and certify rehabilitation specialists in supervised delivery of neuromodulation-plus-physical-therapy protocols.
Company-sponsored multicenter observational and interventional studies to evaluate adherence, functional outcomes, and long-term effects of neuromodulation-plus-therapy programs in MS, stroke, and TBI.
Field-based medical science liaison activities to engage investigators, support publications, respond to medical inquiries, and develop KOL networks.
Expertise Areas
- Clinical trial management
- Neurorehabilitation therapy development
- Regulatory compliance for medical devices
- Real-world evidence and outcomes research
Key Technologies
- Translingual neuromodulation
- Non-invasive neurostimulation
- Portable neurostimulation device engineering
- EEG-based neurophysiological assessment
News & Updates
The company announced a 1-for-50 reverse split of its Class A stock.
CignaHealth becomes the fifth major payer to authorize claim for PoNS Device at negotiated price.
The PoNSTEP study demonstrates durable long-term benefits of PoNS Therapy on gait in MS patients.
The company announced its participation in the 2024 ThinkEquity Conference to showcase its neuromodulation approach for balance and gait deficits.
A project conducted with Pacific Blue Cross and HealthTech Connex demonstrated that PoNS Therapy can help reduce long-term disability and improve quality of life in traumatic brain injury patients.
Helius received FDA breakthrough designation for PoNS therapy to treat gait deficits due to multiple sclerosis.
The company announced a 1-for-50 reverse split of its Class A stock.
CignaHealth becomes the fifth major payer to authorize claim for PoNS Device at negotiated price.
The PoNSTEP study demonstrates durable long-term benefits of PoNS Therapy on gait in MS patients.
The company announced its participation in the 2024 ThinkEquity Conference to showcase its neuromodulation approach for balance and gait deficits.
A project conducted with Pacific Blue Cross and HealthTech Connex demonstrated that PoNS Therapy can help reduce long-term disability and improve quality of life in traumatic brain injury patients.
Helius received FDA breakthrough designation for PoNS therapy to treat gait deficits due to multiple sclerosis.